Tandem Diabetes Care (NASDAQ:TNDM) Lifted to Outperform at Leerink Partnrs

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by equities researchers at Leerink Partnrs from a “market perform” rating to an “outperform” rating in a report released on Thursday, Zacks.com reports.

A number of other brokerages have also recently weighed in on TNDM. Stifel Nicolaus lifted their price objective on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup lifted their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. Finally, SVB Leerink raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $34.00 to $45.00 in a report on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.45.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $35.56 on Thursday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -10.34 and a beta of 1.12. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The stock’s fifty day moving average is $30.74 and its two-hundred day moving average is $25.26.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. On average, research analysts predict that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care during the 4th quarter worth about $27,000. MCF Advisors LLC lifted its holdings in shares of Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Tandem Diabetes Care by 871.8% during the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after buying an additional 1,517 shares during the last quarter. Arcadia Investment Management Corp MI lifted its holdings in shares of Tandem Diabetes Care by 141.6% during the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after buying an additional 1,085 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after buying an additional 1,099 shares during the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.